Compare · ADSEW vs EW
ADSEW vs EW
Side-by-side comparison of ADS-TEC ENERGY PLC Warrant (ADSEW) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- ADSEW operates in Consumer Discretionary, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $49.36B, about 1202.8x ADSEW ($41.0M).
- Over the past year, ADSEW is down 46.1% and EW is up 11.9% - EW leads by 58.0 points.
- EW has hit the wire 6 times in the past 4 weeks while ADSEW has been quiet.
- EW has more recent analyst coverage (25 ratings vs 0 for ADSEW).
- Company
- ADS-TEC ENERGY PLC Warrant
- Edwards Lifesciences Corporation
- Price
- $0.55+17.05%
- $85.67-0.04%
- Market cap
- $41.0M
- $49.36B
- 1M return
- -3.47%
- -1.13%
- 1Y return
- -46.08%
- +11.88%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
ADS-TEC ENERGY PLC Warrant
ADS-TEC Energy PLC, a B2B technology company, develops, manufactures, and services intelligent battery buffered energy systems. The company offers ChargeBox, a battery storage system that integrates inverter, climate control, energy management, security/firewall, and communication units; and ChargeTrailer, a mobile high power charging system in the form of a truck trailer. It also provides PowerBooster, a battery system that delivers high levels of power for the charging process; Storage Rack System, a scalable battery system; and Storage Container System, a custom battery system for large-scale applications as 20- or 40-foot container solutions. The company was founded in 1980 and is based in Dublin, Ireland.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ADSEW
- Amendment: SEC Form SCHEDULE 13D/A filed by ADS-TEC ENERGY PLC Warrant
- SEC Form 6-K filed by ADS-TEC ENERGY PLC Warrant
- SEC Form 20-F filed by ADS-TEC ENERGY PLC Warrant
- Amendment: SEC Form SCHEDULE 13G/A filed by ADS-TEC ENERGY PLC Warrant
- SEC Form 6-K filed by ADS-TEC ENERGY PLC Warrant
- Amendment: SEC Form SCHEDULE 13G/A filed by ADS-TEC ENERGY PLC Warrant
- Amendment: SEC Form 6-K/A filed by ADS-TEC ENERGY PLC Warrant
- Amendment: SEC Form 6-K/A filed by ADS-TEC ENERGY PLC Warrant
- SEC Form 6-K filed by ADS-TEC ENERGY PLC Warrant
- SEC Form 3 filed by new insider Fabritius Andreas
Latest EW
- Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
- CEO Zovighian Bernard J sold $45,982 worth of shares (523 units at $87.92) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 11-K filed by Edwards Lifesciences Corporation